Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc ADR
(NQ:
AZN
)
78.96
-1.57 (-1.95%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,121,062
Open
79.76
Bid (Size)
78.25 (1)
Ask (Size)
78.85 (4)
Prev. Close
80.53
Today's Range
78.62 - 79.99
52wk Range
60.47 - 87.67
Shares Outstanding
N/A
Dividend Yield
1.18%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Moderna To Slash $1.1 Billion From R&D Spending In Major Commercial Push
September 12, 2024
The company says it's investment in R&D has paid off. Now, it needs to move its focus to launching new products.
Via
Investor's Business Daily
AstraZeneca CEO Pascal Soriot Updates On Chinese Compliance Probe And Lung Cancer Drug Trial Results
September 10, 2024
Chinese authorities have detained AstraZeneca employees amid a probe into potential data privacy breaches and unlicensed drug imports. CEO Pascal Soriot assures compliance with Chinese regulations and...
Via
Benzinga
Performance
YTD
+15.44%
+15.44%
1 Month
-5.29%
-5.29%
3 Month
-0.72%
-0.72%
6 Month
+17.78%
+17.78%
1 Year
+18.83%
+18.83%
More News
Read More
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial
September 10, 2024
Via
Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
Via
Benzinga
Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 09, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca Options Trading: A Deep Dive into Market Sentiment
September 05, 2024
Via
Benzinga
Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
September 08, 2024
From
AstraZeneca
Via
Business Wire
3 Market-Beating Stocks to Buy for Less Than $100
September 06, 2024
Via
The Motley Fool
AstraZeneca In Trouble For Employee Detentions in China Over Illegal Activities
September 05, 2024
Via
Benzinga
Topics
Law Enforcement
Exposures
Legal
Reasonable Growth, Debt Levels, and a High ROIC Make ASTRAZENECA PLC-SPONS ADR (NASDAQ:AZN) Appealing to Quality Investors.
September 04, 2024
Via
Chartmill
EXCLUSIVE: Vivani Medical Reveals Positive Preclinical Liver Fat Results From Miniature GLP-1 Implant For Obesity
September 04, 2024
Via
Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
September 03, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
September 03, 2024
From
AstraZeneca
Via
Business Wire
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
August 29, 2024
Via
Investor's Business Daily
Biotech And Life Science Sector Update Summer Of 2024
August 29, 2024
Via
Talk Markets
AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support
August 23, 2024
Via
Benzinga
Biotech Bull Market: 3 Ways To Play It
August 20, 2024
Via
Talk Markets
Topics
Economy
Exposures
Interest Rates
Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested
August 20, 2024
Via
Benzinga
Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave
August 20, 2024
Via
Benzinga
Exposures
Product Safety
10 Health Care Stocks Whale Activity In Today's Session
August 19, 2024
Via
Benzinga
FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer
August 16, 2024
Via
Benzinga
Exposures
Product Safety
IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
August 16, 2024
From
AstraZeneca
Via
Business Wire
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
August 15, 2024
Via
Investor's Business Daily
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
August 15, 2024
From
AstraZeneca
Via
Business Wire
AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding
August 14, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.